Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SPM 962 | Experimental | SPM 962 transdermal patch |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SPM 962 | Drug | SPM 962 transdermal patch once a daily up to 36.0 mg/day |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters | The safety of the long-term SPM 962 treatment was examined based on the incidence and severity of AEs, vital signs, and laboratory parameters. AEs of special interest (1-3) are defined as below:
Application site reaction is scored as -, ±, +, ++, +++, or ++++. More + indicates a greater severity of symptoms. The worst score obtained throughout the evaluation period was to be assessed. | Up to 55 weeks after dosing |
| Measure | Description | Time Frame |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score | Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state). UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kyoji Imaoka, Mr | Otsuka Pharmaceutical Co., Ltd. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chubu Region | Japan | |||||
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | SPM 962 | SPM 962 transdermal patch |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | SPM 962 | SPM 962 transdermal patch |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters | The safety of the long-term SPM 962 treatment was examined based on the incidence and severity of AEs, vital signs, and laboratory parameters. AEs of special interest (1-3) are defined as below:
Application site reaction is scored as -, ±, +, ++, +++, or ++++. More + indicates a greater severity of symptoms. The worst score obtained throughout the evaluation period was to be assessed. | Safety set (SS) | Posted | Number | participants | Up to 55 weeks after dosing |
|
54 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | SPM 962 | SPM 962 transdermal patch |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Colonic Polyp | Gastrointestinal disorders | MedDRA(14.0)J | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | MedDRA(14.0)J | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Director of Clinical Research and Development | Otsuka Pharmaceutical Co., Ltd. | +81-3-6361-7366 |
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C047508 | rotigotine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline, Up to 54 weeks after dosing |
| UPDRS Part 2 Sum Score (Average of on State and Off State) | Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average of on state and off state). UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement. | Baseline, up to 54 weeks after dosing |
| Absolute Time Spent "Off" | Mean number of hours in "off state" during a 24-hour period. | Baseline, up to 54 weeks after dosing |
| UPDRS Part 1 Sum Score | Mean change (LOCF) from baseline in UPDRS Part 1 sum score. UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement. | Baseline, up to 54 weeks after dosing |
| UPDRS Part 2 Sum Score (On State) | Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state). A decrease in the scores means improvement. | Baseline, up to 54 weeks after dosing |
| UPDRS Part 2 Sum Score (Off State) | Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state). A decrease in the scores means improvement. | Baseline, up to 54 weeks after dosing |
| UPDRS Part 4 Sum Score | Mean change (LOCF) from baseline in UPDRS Part 4 sum score. UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement. | Baseline, up to 54 weeks after dosing |
| Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average of on State and Off State), UPDRS Part 3 Sum Score (on State), and UPDRS Part 4 Sum Score | Mean change (LOCF) from baseline in total of UPDRS Part 1 sum score, UPDRS Part 2 sum score (average of on state and off state), UPDRS Part 3 sum score (on state), and UPDRS Part 4 sum score. A decrease in the scores means improvement. | Baseline, up to 54 weeks after dosing |
| The Modified Hoehn & Yahr Severity of Illness | Change (LOCF) from baseline in the Modified Hoehn & Yahr Severity of Illness. The Modified Hoehn & Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided. The data at week 52 is shown. | Baseline, up to 54 weeks after dosing. |
| Each Item of UPDRS Part 1 | The percentage of subjects with elevated scores for each item of UPDRS Part 1. The data at week 52 is shown. | Baseline, up to 54 weeks after dosing. |
| Each Item of UPDRS Part 2 (on State) | The percentage of subjects with elevated scores for each item of UPDRS Part 2 (on state). The data at week 52 is shown. | Baseline, up to 54 weeks after dosing. |
| Each Item of UPDRS Part 2 (Off State) | The percentage of subjects with elevated scores for each item of UPDRS Part 2 (off state). The data at week 52 is shown. | Baseline, up to 54 weeks after dosing. |
| Each Item of UPDRS Part 2 (Average of on State and Off State) | The percentage of subjects with elevated scores for each item of UPDRS Part 2 (average of on state and off state). The data at week 52 is shown. | Baseline, up to 54 weeks after dosing. |
| Total of UPDRS Part 2 Sum Score (Average of on State and Off State) and UPDRS Part 3 Sum Score (on State) | Mean change (LOCF) from baseline in total of UPDRS Part 2 sum score (average of on state and off state) and UPDRS Part 3 sum score (on state). A decrease in the scores means improvement. | Baseline, up to 54 weeks after dosing |
| Each Item of UPDRS Part 3 (on State) | The percentage of subjects with elevated scores for each item of UPDRS Part 3 (on state). The data at week 52 is shown. | Baseline, up to 54 weeks after dosing. |
| Each Item of UPDRS Part 4 | The percentage of subjects with elevated scores for each item of UPDRS Part 4. The data at week 52 is shown. | Baseline, up to 54 weeks after dosing. |
| Chugoku Region |
| Japan |
| Hokkaido Region | Japan |
| Kanto Region | Japan |
| Kinki Region | Japan |
| Kyushu Region | Japan |
| Shikoku Region | Japan |
| Tohoku Region | Japan |
| Protocol Violation |
|
| Discontinuation criteria |
|
| Physician Decision |
|
| years |
|
| Age, Categorical | Count of Participants | Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Secondary | Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score | Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state). UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement. | Full analysis set (FAS), last observation carried forward (LOCF) | Posted | Mean | Standard Deviation | Scores on a scale | Baseline, Up to 54 weeks after dosing |
|
|
|
| Secondary | UPDRS Part 2 Sum Score (Average of on State and Off State) | Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average of on state and off state). UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement. | FAS, LOCF | Posted | Mean | Standard Deviation | Scores on a scale | Baseline, up to 54 weeks after dosing |
|
|
|
| Secondary | Absolute Time Spent "Off" | Mean number of hours in "off state" during a 24-hour period. | FAS subjects with measurable off time at baseline, LOCF | Posted | Mean | Standard Deviation | Hours | Baseline, up to 54 weeks after dosing |
|
|
|
| Secondary | UPDRS Part 1 Sum Score | Mean change (LOCF) from baseline in UPDRS Part 1 sum score. UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement. | FAS, LOCF | Posted | Mean | Standard Deviation | Scores on a scale | Baseline, up to 54 weeks after dosing |
|
|
|
| Secondary | UPDRS Part 2 Sum Score (On State) | Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state). A decrease in the scores means improvement. | FAS, LOCF | Posted | Mean | Standard Deviation | Scores on a scale | Baseline, up to 54 weeks after dosing |
|
|
|
| Secondary | UPDRS Part 2 Sum Score (Off State) | Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state). A decrease in the scores means improvement. | FAS, LOCF | Posted | Mean | Standard Deviation | Scores on a scale | Baseline, up to 54 weeks after dosing |
|
|
|
| Secondary | UPDRS Part 4 Sum Score | Mean change (LOCF) from baseline in UPDRS Part 4 sum score. UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement. | FAS, LOCF | Posted | Mean | Standard Deviation | Scores on a scale | Baseline, up to 54 weeks after dosing |
|
|
|
| Secondary | Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average of on State and Off State), UPDRS Part 3 Sum Score (on State), and UPDRS Part 4 Sum Score | Mean change (LOCF) from baseline in total of UPDRS Part 1 sum score, UPDRS Part 2 sum score (average of on state and off state), UPDRS Part 3 sum score (on state), and UPDRS Part 4 sum score. A decrease in the scores means improvement. | FAS, LOCF | Posted | Mean | Standard Deviation | Scores on a scale | Baseline, up to 54 weeks after dosing |
|
|
|
| Secondary | The Modified Hoehn & Yahr Severity of Illness | Change (LOCF) from baseline in the Modified Hoehn & Yahr Severity of Illness. The Modified Hoehn & Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided. The data at week 52 is shown. | FAS, LOCF | Posted | Number | Percentage of participants | Baseline, up to 54 weeks after dosing. |
|
|
|
| Secondary | Each Item of UPDRS Part 1 | The percentage of subjects with elevated scores for each item of UPDRS Part 1. The data at week 52 is shown. | FAS, LOCF | Posted | Number | Percentage of Participants | Baseline, up to 54 weeks after dosing. |
|
|
|
| Secondary | Each Item of UPDRS Part 2 (on State) | The percentage of subjects with elevated scores for each item of UPDRS Part 2 (on state). The data at week 52 is shown. | FAS, LOCF | Posted | Number | Percentage of Participants | Baseline, up to 54 weeks after dosing. |
|
|
|
| Secondary | Each Item of UPDRS Part 2 (Off State) | The percentage of subjects with elevated scores for each item of UPDRS Part 2 (off state). The data at week 52 is shown. | FAS, LOCF | Posted | Number | Percentage of Participants | Baseline, up to 54 weeks after dosing. |
|
|
|
| Secondary | Each Item of UPDRS Part 2 (Average of on State and Off State) | The percentage of subjects with elevated scores for each item of UPDRS Part 2 (average of on state and off state). The data at week 52 is shown. | FAS, LOCF | Posted | Number | Percentage of Participants | Baseline, up to 54 weeks after dosing. |
|
|
|
| Secondary | Total of UPDRS Part 2 Sum Score (Average of on State and Off State) and UPDRS Part 3 Sum Score (on State) | Mean change (LOCF) from baseline in total of UPDRS Part 2 sum score (average of on state and off state) and UPDRS Part 3 sum score (on state). A decrease in the scores means improvement. | FAS, LOCF | Posted | Mean | Standard Deviation | Scores on a scale | Baseline, up to 54 weeks after dosing |
|
|
|
| Secondary | Each Item of UPDRS Part 3 (on State) | The percentage of subjects with elevated scores for each item of UPDRS Part 3 (on state). The data at week 52 is shown. | FAS, LOCF | Posted | Number | Percentage of Participants | Baseline, up to 54 weeks after dosing. |
|
|
|
| Secondary | Each Item of UPDRS Part 4 | The percentage of subjects with elevated scores for each item of UPDRS Part 4. The data at week 52 is shown. | FAS, LOCF | Posted | Number | Percentage of Participants | Baseline, up to 54 weeks after dosing. |
|
|
|
| 34 |
| 321 |
| 290 |
| 321 |
| Gastric Ulcer Bleeding | Gastrointestinal disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Haemorrhoids | Gastrointestinal disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Hernia Inguinal | Gastrointestinal disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Sudden Death | General disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Cholecystitis | Hepatobiliary disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Herpes Zoster | Infections and infestations | MedDRA(14.0)J | Non-systematic Assessment |
|
| Osteomyelitis | Infections and infestations | MedDRA(14.0)J | Non-systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA(14.0)J | Non-systematic Assessment |
|
| Septicaemia | Infections and infestations | MedDRA(14.0)J | Non-systematic Assessment |
|
| Urinary Tract Infection | Infections and infestations | MedDRA(14.0)J | Non-systematic Assessment |
|
| Femur Fracture | Injury, poisoning and procedural complications | MedDRA(14.0)J | Non-systematic Assessment |
|
| Haematoma Subdural | Injury, poisoning and procedural complications | MedDRA(14.0)J | Non-systematic Assessment |
|
| Heat Illness | Injury, poisoning and procedural complications | MedDRA(14.0)J | Non-systematic Assessment |
|
| Hip Fracture | Injury, poisoning and procedural complications | MedDRA(14.0)J | Non-systematic Assessment |
|
| Jaw Fracture | Injury, poisoning and procedural complications | MedDRA(14.0)J | Non-systematic Assessment |
|
| Radius Fracture | Injury, poisoning and procedural complications | MedDRA(14.0)J | Non-systematic Assessment |
|
| Spinal Compression Fracture | Injury, poisoning and procedural complications | MedDRA(14.0)J | Non-systematic Assessment |
|
| Ulna Fracture | Injury, poisoning and procedural complications | MedDRA(14.0)J | Non-systematic Assessment |
|
| Upper Limb Fracture | Injury, poisoning and procedural complications | MedDRA(14.0)J | Non-systematic Assessment |
|
| Dehydration | Metabolism and nutrition disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Back Pain | Musculoskeletal and connective tissue disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Intervertebral Disc Protrusion | Musculoskeletal and connective tissue disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Rhabdomyolysis | Musculoskeletal and connective tissue disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Breast Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA(14.0)J | Non-systematic Assessment |
|
| Gastric Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA(14.0)J | Non-systematic Assessment |
|
| Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA(14.0)J | Non-systematic Assessment |
|
| Large Intestine Carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA(14.0)J | Non-systematic Assessment |
|
| Carpal Tunnel Syndrome | Nervous system disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Depressed Level Of Consciousness | Nervous system disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Disease Parkinson's | Nervous system disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Delirium | Psychiatric disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Hallucination Visual | Psychiatric disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Somnolence | Psychiatric disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Dental Caries | Gastrointestinal disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Stomatitis | Gastrointestinal disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Application Site Reaction | General disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Application Site Pruritus | General disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Oedema Peripheral | General disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Application Site Erythema | General disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA(14.0)J | Non-systematic Assessment |
|
| Cystitis | Infections and infestations | MedDRA(14.0)J | Non-systematic Assessment |
|
| Contusion | Injury, poisoning and procedural complications | MedDRA(14.0)J | Non-systematic Assessment |
|
| Blood Creatine Phosphokinase Increased | Investigations | MedDRA(14.0)J | Non-systematic Assessment |
|
| Weight Decreased | Investigations | MedDRA(14.0)J | Non-systematic Assessment |
|
| Back Pain | Musculoskeletal and connective tissue disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Pain In Extremity | Musculoskeletal and connective tissue disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Dyskinesia | Nervous system disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Posture Abnormal | Nervous system disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Hallucination Visual | Psychiatric disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Somnolence | Psychiatric disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Hallucination | Psychiatric disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Insomnia | Psychiatric disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Upper Respiratory Tract Inflammation | Respiratory, thoracic and mediastinal disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
| Orthostatic Hypotension | Vascular disorders | MedDRA(14.0)J | Non-systematic Assessment |
|
Not provided
Not provided
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
|
| Title | Measurements |
|---|---|
|
|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Motivation/Initiative |
|
| Handwriting |
|
| Cutting Food and Handling Utensils |
|
| Dressing |
|
| Hygiene |
|
| Turning in Bed / Adjusting Bed Clothes |
|
| Falling - Unrelated to Freezing |
|
| Freezing When Walking |
|
| Walking |
|
| Tremor |
|
| Sensory Complaints Related to Parkinsonism |
|
| Handwriting |
|
| Cutting Food and Handling Utensils |
|
| Dressing |
|
| Hygiene |
|
| Turning in Bed / Adjusting Bed Clothes |
|
| Falling - Unrelated to Freezing |
|
| Freezing When Walking |
|
| Walking |
|
| Tremor |
|
| Sensory Complaints Related to Parkinsonism |
|
|
| Handwriting |
|
| Cutting Food and Handling Utensils |
|
| Dressing |
|
| Hygiene |
|
| Turning in Bed / Adjusting Bed Clothes |
|
| Falling - Unrelated to Freezing |
|
| Freezing When Walking |
|
| Walking |
|
| Tremor |
|
| Sensory Complaints Related to Parkinsonism |
|
| Title | Measurements |
|---|
|
| Tremor at Rest (Left hand) |
|
| Tremor at Rest (Right hand) |
|
| Tremor at Rest (Left foot) |
|
| Tremor at Rest (Right foot) |
|
| Action or Postural Tremor of Hands (Left hand) |
|
| Action or Postural Tremor of Hands (Right hand) |
|
| Rigidity (Neck) |
|
| Rigidity (Left upper extremity) |
|
| Rigidity (Right upper extremity) |
|
| Rigidity (Left lower extremity) |
|
| Rigidity (Right lower extremity) |
|
| Finger Taps (Left) |
|
| Finger Taps (Right) |
|
| Hand Movements (Left) |
|
| Hand Movements (Right) |
|
| Rapid Alternating Movements of Hands (Left) |
|
| Rapid Alternating Movements of Hands (Right) |
|
| Leg Agility (Left) |
|
| Leg Agility (Right) |
|
| Arising From Chair |
|
| Posture Erect |
|
| Gait |
|
| Postural Stability |
|
| Body Bradykinesia / Hypokinesia |
|
| Presence of Early Morning Dystonia |
|
| Are "off" periods predictable? |
|
| Are "off" periods unpredictable? |
|
| Do "off" periods come on suddenly? |
|
| Proportion of "off" in waking day |
|
| Patients with anorexia, nausea, or vomiting |
|
| Patients with any sleep disturbances |
|
| Patient with symptomatic orthostasis |
|